Cargando…
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity
Curative cancer therapies are uncommon and nearly always involve multi-drug combinations developed by experimentation in humans; unfortunately, the mechanistic basis for the success of such combinations has rarely been investigated in detail, obscuring lessons learned. Here, we use isobologram analy...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
eLife Sciences Publications, Ltd
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897534/ https://www.ncbi.nlm.nih.gov/pubmed/31742555 http://dx.doi.org/10.7554/eLife.50036 |